Sintilimab plus decitabine for higher-risk treatment-naïve myelodysplastic syndromes: efficacy, safety, and biomarker analysis of a phase II, single-arm trial

Sintilimab plus decitabine for higher-risk treatment-naïve myelodysplastic syndromes: efficacy, safety, and biomarker analysis of a phase II, single-arm trial

Background Immunotherapy combined with azacitidine was feasible in higher-risk myelodysplastic syndromes (MDSs) with limited sample size of treatment-naïve patients, while the optimization of treatment strategies, including the optimal immune checkpoint inhibitor and hypomethylating agent and possib...

Full description

Saved in:
Bibliographic Details
Main Authors: Jing Wang, Ying-Jun Chang, Xiaohong Liu, Wenjing Yu, Hao Jiang, Xiaojun Huang, Siqi Li, Xiaosu Zhao, Jinsong Jia, Xiaolu Zhu, Lizhong Gong
Format: Article
Language:English
Published: BMJ Publishing Group 2024-11-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/12/11/e010355.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items